The Hantavirus Scare Brought 3 Covid-Era Stocks Back in the Spotlight

The hantavirus outbreak on the MV Hondius lifted one mRNA leader 36% off May lows before profit-taking trimmed the rally. The brief move reactivated the pandemic-prep trade across medical stocks, putting three Covid-era stocks back on the 2026 comeback watchlist. Each setup carries a different signal. One name has already moved on to the mRNA platform strength. Another builds an inverse base as the biodefense contractor. The third offers a contrarian play loaded with bears. May 2026 is when each chart picks a side. Note: mRNA, short for messenger RNA, is the vaccine platform behind the COVID-19 shots, delivering genetic instructions to cells instead of using a live virus. Moderna (NASDAQ: MRNA) Among the Covid-era stocks rotating back into focus, Moderna stock rallied 36.08% from $43.69 on May 1 to $59.45 on May 11. Volume rose alongside price throughout the climb, confirming buying pressure rather than short covering. Want more insights like this? Sign up for Editor Harsh Notariya’s Daily Newsletter here. Three catalysts drove the move. Q1 2026 revenue grew 260% year-over-year to $389 million; the company disclosed a hantavirus vaccine collaboration with the US Army Medical Research Institute of Infectious Diseases; and Phase 3 mRNA-1010 flu data were published in the New England Journal of Medicine. $MRNA Q1 2026 earnings: Strong Revenue Rebound Masked by Massive Litigation ChargeModerna delivered a solid start to 2026 with $389 million in total revenue (+260% YoY), driven by international deliveries. However, an $878 million litigation settlement with Arbutus pushed the… pic.twitter.com/IONI4tFdHW— Finsee (@Finsee_main) May 1, 2026 Moderna’s price now sits near $54.05, consolidating in what resembles the handle of a cup-and-handle continuation pattern. The cup bottom anchors at $43.69, and the rim sits near $59.45. The handle is forming above the 20-day Exponential Moving Average (EMA), a trend indicator that weights recent price action more heavily, currently...